US 11,993,644 B2
Antigen binding molecules targeting SARS-CoV-2
Francesco Borriello, Cambridge, MA (US); and Alexis Hiram Ramos, Wilbraham, MA (US)
Assigned to Generate Biomedicines, Inc., Somerville, MA (US)
Filed by Generate Biomedicines, Inc., Somerville, MA (US)
Filed on May 5, 2023, as Appl. No. 18/313,306.
Claims priority of provisional application 63/492,206, filed on Mar. 24, 2023.
Claims priority of provisional application 63/480,903, filed on Jan. 20, 2023.
Claims priority of provisional application 63/478,650, filed on Jan. 5, 2023.
Claims priority of provisional application 63/385,957, filed on Dec. 2, 2022.
Claims priority of provisional application 63/383,695, filed on Nov. 14, 2022.
Claims priority of provisional application 63/424,945, filed on Nov. 13, 2022.
Claims priority of provisional application 63/381,131, filed on Oct. 26, 2022.
Claims priority of provisional application 63/381,132, filed on Oct. 26, 2022.
Claims priority of provisional application 63/364,328, filed on May 6, 2022.
Claims priority of provisional application 63/364,331, filed on May 6, 2022.
Prior Publication US 2023/0357366 A1, Nov. 9, 2023
Int. Cl. C07K 16/10 (2006.01); A61K 31/13 (2006.01); A61K 31/215 (2006.01); A61K 31/45 (2006.01); A61K 31/4706 (2006.01); A61K 31/4965 (2006.01); A61K 31/675 (2006.01); A61K 31/7052 (2006.01); A61K 31/7068 (2006.01); A61K 31/7088 (2006.01); A61K 39/215 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1003 (2023.08) [A61K 31/13 (2013.01); A61K 31/215 (2013.01); A61K 31/45 (2013.01); A61K 31/4706 (2013.01); A61K 31/4965 (2013.01); A61K 31/675 (2013.01); A61K 31/7052 (2013.01); A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 39/215 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] 30 Claims
 
1. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike) comprising:
a) a heavy chain variable domain (VH) that comprises a heavy chain complementarity-determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:77, a HCDR2 comprising the amino acid sequence of SEQ ID NO:80, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:91; and
b) a light chain variable domain (VL) that comprises a light chain complementarity-determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:133, a LCDR2 comprising the amino acid sequence of SEQ ID NO:141, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:144, wherein the polypeptide is an antibody or an antigen-binding fragment thereof.